Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...